A Heart Disease Cure For Pericarditis? Phase 3 Trial Advances | David Elsley – Cardiol Therapeutics

FULL DISCLOSURE: This is sponsored content for Cardiol Therapeutics.

Discover the major breakthrough at Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL) as CEO David Elsley reveals the enrollment of their first patient in the pivotal Phase 3 MAVERIC trial for recurrent pericarditis. In this concise interview, Elsley discusses how their oral drug therapy aims to prevent new episodes of this debilitating heart condition, the impressive Phase 2 results showing significant pain reduction, and the potential timeline for market entry by mid-2026.

With trial sites at prestigious institutions like Mass General, Cleveland Clinic, and Mayo Clinic, and a market potential approaching $1 billion by 2028, investors won’t want to miss this significant development in cardiovascular medicine.

FULL DISCLOSURE: Cardiol Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of Cardiol Therapeutics. The author has been compensated to cover Cardiol Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. We may buy or sell securities in the company at any time. Always do additional research and consult a professional before purchasing a security.